Artivila Biopharma Secures Nearly RMB 100 Million in Series A Funding to Advance AI-Driven Small and Large Molecule Drug Development

▲94-5th   CBI Biopharmaceutical Innovation Expo Scan the QR Code to Register

Note:This article does not constitute any investment advice or recommendations; please refer to the official/company announcements for authoritative information;This article is intended solely for the introduction of medications related to medical and healthcare purposes. It does not constitute a recommendation for treatment plans (if any), nor does it represent the platform's stance.Authorization is required for any article reprints.

PharmaCircle DataMonitoring shows: June 2026, Artivila(Artivila Biopharma)Recently successfully completedNearhundred million yuanASeries A financing.

This round of financing was led by Sinovest Capital, with follow-on investments from Junyi Investment and others. The funds will be primarily used to strengthen the R&D platform and product pipeline development, support company operations, and expand international business development, particularly focusing on the clinical development and indication expansion of core pipelines.INDDeclaration.

To date, Artivila’s cumulative financing amounts to nearly4hundred million yuan, fully reflecting the capital market’s high recognition of the competitiveness of the company’s platform and innovative drug pipeline as well as its long-term growth potential, thereby supporting the achievement of its long-term strategic objectives.

Zhu Zhendong, Founder and Chairman of ArtivilaDr.and Co-founder,CEODr. Deqiang NiuJointly represent: Artivila relies on solidAIPlatform and Global Leading R&D Pipeline CompletionAround of financing. We sincerely thank the investors for their recognition and support of Artivila. This round of financing will accelerate the advancement of our core pipeline and our international expansion. Artivila will remain committed to‘Diligence and Innovation’the original aspiration, withAIRedefining the speed and precision of new drug development to deliver innovative treatment solutions to patients worldwide sooner.

Dual-targetIRAK4/1InhibitorARD-885；in the field of neurological diseasesSARM1Inhibitor; bispecific antibodies in the oncology field are under investigation.

Attachment, Sharing:

Follow the “Yaorongquan” WeChat Official Account to receive updates on new drug information. For learning and sharing purposes only; not intended as investment advice or recommendations!

References:

PharmCube Data;

FDA/EMA；

NMPA；

https://www.sec.gov/Archives/edgar/data；

https://www.businesswire.com；

https://lifescivoice.com；

https://www.globenewswire.com/n

ews-release；

https://www.businesswire.com/news/home；

Wait.